Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Ya Chen Tina ShihYing XuChun-Ru ChienBumyang KimYu ShenLiang LiDaniel M GeynismanPublished in: PharmacoEconomics (2020)
The rising economic burden of RCC was most pronounced among patients with distant-stage RCC, and driven primarily by new cancer drugs.